한 문단으로 보기
Verve had a single idea: instead of taking cholesterol medication every day for life, switch off the gene that raises cholesterol, once. Its lead treatment reached patients and showed lasting reductions in LDL cholesterol. Eli Lilly bought the company in 2025 and continues the programme.
Verve Therapeutics was founded in 2018 by Sekar Kathiresan and Kiran Musunuru to apply in vivo base editing to cardiovascular disease, licensing base-editing technology from Beam Therapeutics. VERVE-102 targets PCSK9 and holds FDA Fast Track designation. Eli Lilly acquired the company in 2025 for approximately $1 billion, plus a contingent value right tied to dosing the first patient in a US Phase 3 trial.
Sources
- Eli Lilly and Company · 2025
Lilly to acquire Verve Therapeutics ↗
투자 조언이 아닙니다
이 프로필은 공개된 자료를 바탕으로 작성된 교육용 정보입니다. 특정 유가증권의 매수·매도·보유를 권장하는 내용이 아니며, 해당 기업의 전망에 대한 견해도 아닙니다. 바이오테크놀로지는 투기적 성격이 강하며, 대부분의 임상 프로그램은 실패합니다.
전체 면책 조항 →